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Objectives. To assess the eﬃcacy and safety of injectable midazolam administered orally in 3 diﬀerent doses in children undergoing
complete dental rehabilitation under GA. Subjects and Methods. 60 children aged 2–6 years were enrolled in the study. The
children were randomly assigned to one of 3 groups and received orally 0.5, 0.75, or 1.0mg/kg of injectable midazolam mixed
with apple juice 30 minutes before separation from parents. The following measurements were assessed: patient’s acceptance of the
medication,reactiontoseparationfromparents,sedationscores,andrecoveryconditions. Results.Morechildrenwerecomfortable
with parent separation in the group that received the 1.0mg/kg dose (90%) compared to the group that received the 0.75mg/kg
dose (75%) and the group that received the 0.5mg/kg dose (55%). The number of children who had desirable sedation was similar
in the 0.75mg/kg and 1.0mg/kg dose groups. Twenty ﬁve percent of the children in the group that received the 0.5mg/kg dose did
notallowvenepuncturebeforeinductionofGA,andinductionofGAwaspoorfor20%ofthechildreninthisgroup.Anincreasing
number of children scored excellent in terms of ease of venepuncture in 0.75mg/kg dose group (10%) and in the 1.0mg/kg dose
group(20%)andintermsofinductionofGA,25%and35%,respectively.Recoveryofspontaneousventilationandextubationwas
delayed by over 15 minutes in 2 children in the 1.0mg/kg dose group. Conclusion. The dose of 0.75mg/kg of injectable midazolam
given orally as premedication is acceptable, eﬀective, and safe.
Copyright © 2009 S. A. Sheta and M. AlSarheed. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
It is generally agreed that most children who are undergoing
medical procedures and who are fearful and uncooperative
can and should be managed with behavioral (nonphar-
macologic) management techniques. Unfortunately, a small
percentage of pediatric patients cannot be successfully
managed solely with these techniques [1]. When behavioral
management strategies fail, some form of pharmacologic
sedation or anesthesia becomes a valuable and necessary
alternative. Children who are undergoing dental procedures
and who are extremely uncooperative, fearful, anxious,
or physically resistant with no expectation of behavior
improvement are candidates for general anaesthesia (GA)
[2].
An eﬀective premedication may facilitate a smoother
induction of GA with minimal hemodynamic alterations
and minimize the emotional trauma in children undergoing
surgery. Premedication is best given by an oral route in
children as children often exhibit an exaggerated psycho-
logical response to a needle, and it is easier to distribute a
medication orally than to use nasal or rectal routes [3, 4].
Midazolam, with its rapid onset and relatively short
duration of action, has proven to be a useful premedication
to decrease preoperative anxiety and facilitate separation
from parents with fewer unwanted side eﬀects [5]. However,
an oral preparation of midazolam is not commercially
available in some countries. Doses of injectable midazolam
mixed with apple juice were used in this study as an oral
premedication.2 International Journal of Pediatrics
The objectives ofthis study weretoassessthe eﬃcacyand
safety of oral injectable midazolam in three diﬀerent doses
and to determine the optimal dose as a premedication in
children undergoing complete dental rehabilitation.
2.SubjectsandMethods
The study protocol received institutional approval from
the Ethics Committee of the College of Dentistry Research
Center (CDRC) of the King Saud University in Riyadh, Saudi
Arabia. Written informed consent was obtained from at least
one of the parents, and verbal consent from the child was
sought whenever possible.
Sixty children were selected from those visiting Pediatric
Dentistry Clinics in the College of Dentistry, King Saud
University. Healthy children (ASA I & II) aged 2 to 6
years within normal range of weight who were scheduled
for complete dental rehabilitation under general anesthesia
(GA) on an outpatient basis were enrolled in the study
protocol. Children who were referred to GA, according
to the protocol adopted in Dental College, had a rating
of 1 (deﬁnitely negative) according to Frankl behavior
category scales rating [6]. These children refused treatment,
were extremely uncooperative, were anxious, cried forcefully
or fearfully, or displayed any overt evidence of extreme
negativism.
Children were excluded from the study if they were
hemodynamically or respiratory unstable, had any mental
retardation or physical disabilities, were under treatment
with sedatives or anticonvulsants, or if their parents refused
to allow them to participate.
The study was designed as randomized double blinded
study. The original study plan was to include a control group
(placebo group). However, in a pilot study, the ﬁrst few
children who received no premedication were anxious and
agitated. We believed that it was not ethical to expose them
to such suﬀering and decided to exclude the control group
from the study. Therefore, children were randomly assigned
by sealed envelope technique to one of three groups, each
containing 20 participants.
Groups A, B, and C received an oral administration
of 0.5mg/kg, 0.75mg/kg, and 1.0mg/kg, respectively, of
injectable midazolam mixed in apple juice, 30 minutes
before separation from parents (premedication time). Oral
midazolam is not available commercially in Saudi Arabia.
An injectable 5mg/mL preparation of midazolam was used,
thus limiting the total volume mixed with a double volume
of apple juice.
The drug was prepared and administered by the pre-
operative room nurse based on the patient’s assigned
group, so that the anesthesiologists, dentists, and the Post
Anesthesia Care Unit (PACU) nurse remained blinded
to the groups. The PACU nurse was responsible for
recording participants’ heart rate, blood pressure, respira-
tory rate, oxygen saturation (SaO2), reaction to separa-
tion from parents, and sedation scores including ease of
venepuncture. The PACU nurse also observed induction of
GA.
All children received a standardized GA by the same
anesthesiologist. The anesthesiologist used sevoﬂurane or
propofol induction (if an intravenous line could be estab-
lished before induction) in a dose of 2mg/kg. There-
after, 2µg/kg of fentanyl and 0.5mg/kg of atracurium
were injected to facilitate tracheal intubation. After nasal
preparation with a vasoconstrictor (oxymetazoline), a nasal
endotracheal tube of the appropriate size was inserted.
Then, a pharyngeal throat pack was introduced. Sevoﬂurane
was the inhalational anesthetic used for maintenance of
anesthesia. Ventilation was controlled to maintain nor-
mocapnia (PetCO2 32–38mmHg). Patients’ electrocardio-
gram, noninvasive arterial blood pressure, pulse oximetry,
temperature, and inspiratory and expiratory gas concen-
trations were monitored as part of standard GA proce-
dure.
For postoperative analgesia, an injection of 0.5mg/kg
of ketorolac was given intramuscularly 30 minutes before
the anticipated end of surgery and repeated after every 6–
8 hours. Local anesthetic inﬁltration (xylocaine 20mg/mL
and adrenaline 12.5µg/mL) was administered by the dentist
before tooth extraction. The dentist’s conﬁrmation that
bleeding at the sites of extraction was controlled deﬁned
the end of surgery. The throat pack was then removed, and
the inhalational anesthetics were discontinued. Reversal of
muscle relaxation and recovery of neuromuscular function
were conﬁrmed using the train-of-four (TOF) method [7].
A nerve stimulator applied to the ulnar nerve was used for
intraoperative monitoring of muscle relaxant.
The fresh gas ﬂow was increased to 10L/min in all
3 groups. Tracheal extubation was performed when nor-
moventilation was achieved and the patients regained gag or
cough reﬂex. Thereafter, all patients were transferred to the
PACU. The duration of exposure to volatile anesthetics was
recorded by an observer blinded to anesthetic management.
Recovery monitoring was performed for all patients
during their stay in the PACU according to the standard
protocol of our institution. No patient was returned to the
ambulatory unit earlier than 30 minutes after completion of
the procedure.
GA induction, recovery conditions, and side eﬀects were
recorded by an independent PACU nurse who was also
blinded to the premedication dose.
2.1. Assessments
2.1.1. Patient’s Acceptance of the Medication. Acceptance of
the medication was deﬁned as swallowing without immedi-
ate regurgitation. The preoperative room nurse was asked to
addextra patientstothesamegroupif anyofthepatientsdid
not accept the medication or vomited soon after ingestion.
Thus, the number of patients in each group remained equal
f o rf u r t h e ro b s e r v a t i o n .
2.1.2. Reaction to Separation from Parents. The response
of the children when taken away from the parents was
recorded as the end point of premedication. It was graded
as inconsolable cry, complaining, quiet but awake, or sleepy.International Journal of Pediatrics 3
Table 1: Sedation Grades.
Grade Description
I Anxious, agitated
II Oriented, calm, cooperative
III Drowsy, responding to verbal commands
IV Not responding to verbal commands but to painful stimuli
V Not responding to painful stimuli
Table 2: Pilot sample results.
Criteria Results (no. of patients)
No. of patients 5
Types of premedication None
Reaction to separation from parents Inconsolable cry (5)
Sedation score at OR Extremely anxious (5)
Ease of venepuncture Poor (5)
Induction score Poor (5)
2.1.3.SedationScores. Thedegreeofsedation,whenthechild
wasﬁrstseenintheoperatingroom(OR)andattheendafter
reversal of residual paralysis, was based upon the 5 points
sedation score, given in Table 1 [8].
2.1.4. Ease of Venepuncture and Induction of GA. Both ease
of venepuncture and induction of GA were graded as poor,
fair, good, or excellent depending upon the individual child’s
response in the OR.
2.1.5. Recovery Conditions. We looked for spontaneous
ventilation after giving the reversal and noted the time
required for establishing adequate spontaneous ventilation
followed by endotracheal extubation. We noted the need to
supplement oxygen for maintaining >95% SaO2.
2.1.6. Statistical Analysis. Statistical analysis was performed
using SPSS version 13 (SPSS Inc., Chicago, Fl, USA).
Demographic variables and duration of anesthesia were
compared using ANOVAs test, whereas the results were
compared within groups using Chi Square analysis. Also,
a nonparametric test was used to compare continuous
data values. A P-value of <.05 was considered statistically
signiﬁcant.
3. Results
All children in the pilot study (without premedication) were
extremely anxious and cried inconsolably when they were
separated from their parent(s). When these children were
ﬁrst seen in the OR, venepuncture was impossible, and we
decided to induce GA and to exclude them from the study
(Table 2).
All treatment groups were comparable with respect to
ASA status, gender, age, weight, and duration of anesthesia
as shown in Table 3. During the premedication time, none
of the patients in the study had an incidence of bradycar-
dia (heart rate <20% baseline), hypotension (mean blood
pressure <20% of baseline) or desaturation episodes (O2
saturation <95%) according to the preoperative room nurse.
3.1. Acceptance and Vomiting soon after Ingestion of the
Premedication. Data showed that the acceptability of the
medication was similar across the groups. One hundred
percent of the children in the groups receiving 0.5mg/kg
and 1.0mg/kg doses of midalozam and 95% in the group
receiving the 0.75mg/kg dose accepted the treatment. None
of the patients in any of the groups vomited soon after
swallowing the premedication.
3.2. Reaction to Separation from Parents. The children’s
reaction to being separated from their parent(s) 30 minutes
after receiving premedication is displayed in Table 4.W e
found that none of the children in the 1.0mg/kg dose group
cried compared with 4 children (20%) in the 0.5mg/kg dose
group and one child (5%) in the 0.75mg/kg dose group.
The percentage of children who appeared uncomfortable
(study nurse recorded that they were crying or complaining)
were the highest in the 0.5mg/kg dose group (45%). Only
25% of the children in the 0.75mg/kg dose group and
10% of the children in the 1.0mg/kg dose group appeared
uncomfortable.Thus more children were comfortable (study
nurse recorded they were sleepy or quite but awake) in the
1.0mg/kg dose group (90%) compared with the 0.75mg/kg
dose group (75%) and the 0.5mg/kg dose group (55%). This
diﬀerence was statistically signiﬁcant between the group that
received the 0.5mg/kg dose and the group that received the
1.0mg/kg dose (P<. 05).
3.3. Level of Sedation after Premedication. All children were
observed in the operating room before the induction of
GA. None of the children in the 1.0mg/kg dose group
appeared to be anxious while 7 (35%) of the children in
0.5mg/kg dose group and 3 (15%) of the children in the
0.75mg/kg dose group appeared to be anxious (Table 5). A
statisticallysigniﬁcantdiﬀerence(P<. 005)inthepercentage
of patients who were satisfactorily sedated but could be
arousedexistedbetweenthe1.0mg/kgdosegroup(40%)and
the 0.5mg/kg dose group (15%). The number of patients
who had desirable sedation (oriented or calm or drowsy
but responding to verbal commands) was similar (80%) in
groups receiving the 1.0mg/kg and 0.75mg/kg doses. Four
children (20%) in the group that received the 1.0mg/kg dose
experienced deep sedation, characterized as not responding
to verbal commands but to painful stimuli, whereas only
one child (5%) had deep sedation in the 0.75mg/kg dose
group. There were no incidences in this study of children not
responding to painful stimuli (Table 5).
3.4. Ease of Venepuncture and Induction of GA. Twenty-ﬁve
percent of the children in the 0.5mg/kg dose group received
a rating of poor for ease of venepuncture (Table 6). None
of the patients in this group received a rating of excellent
on this measure. In comparison, 10% of the children in
the 0.75mg/kg dose group and 20% of the children in the
1.0mg/kg received a rating of excellent. Four of the children4 International Journal of Pediatrics
Table 3: Patient characteristics.
Groups A B C
Midazolam Dose (0.5mg/kg) (0.75mg/kg) (1.0mg/kg)
Age mean (+SD) 4(1.026) 3.85(1.22) 4.30(1.30)
ASA I/II∗ 18/2 18/2 19/1
Gender (M/F) 9/11 10/10 8/12
Weight mean (kg) (+SD) 20.40(3.26) 19.85(3.52) 20.20(3.51)
Duration (min) of general anesthesia 122.75 120.75 123.50
∗Number of patients
Table 4: Reaction to parent’s separation.
Groups A B C
Midazolam Dose 0.5mg/kg no. (%) 0.75mg/kg no. (%) 1.0mg/kg no. (%)
Inconsolable cry 4(20) 1(5) 0
Complaining 5(25) 4(20) 2(10)
Total number of uncomfortable children 9(45) 5(25) 2(10)
Quiet-but-awake 10(50) 13(65) 13(65)
Sleepy 1(5) 2(10) 5(25)
Total number of comfortable children 11(55) 15(75) 18(90)a
aP ≤ .05 versus group A
Table 5: Sedation score in OR (preoperative). RVC, responding to verbal commands.
Group A B C
Midazolam Dose 0.5mg/kg no. (%) 0.75mg/kg no. (%) 1.0mg/kg no. (%)
Anxious 7(35) 3(15) 0
Oriented, calm 10(50) 11(55) 8(40)
Drowsy-RVC 3(15) 5(25) 8(40)a
Not RVC but to painful stimuli 0 1(5) 4(20)
Not responding to painful stimuli 0 0 0
aP ≤ .005 versus group A
Table 6: The ease of venepuncture and induction of GA (IV/Mask).
Ease of venepuncture Induction score
ABC ABC
0.5mg/kg no. (%) 0.75mg/kg no. (%) 1.0mg/kg no. (%) 0.5mg/kg no. (%) 0.75mg/kg no. (%) 1.0mg/kg no. (%)
Poor 5(25) 3(15) 1(5) 4(20) 1(5) 0
Fair 8(40) 6(30) 4(20) 7(35) 4(20) 3(15)
Total 13(65) 9(45) 5(25) 11(55) 5(25) 3(15)
Good 7(35) 9(45) 11(55) 8(40) 10(50) 10(50)
Excellent 0 2(10) 4(20) 1(5) 5(25) 7(35)
Total 7(35) 11(55) 15(75) 9(45) 15(75)a 17(85)a
aP ≤ .05 versus group A
Table 7: Sedation score on reversal of residual paralysis. RVC, responding to verbal commands.
Groups A B C
Midazolam Dose 0.5mg/kg no. (%) 0.75mg/kg no. (%) 1.0mg/kg no. (%)
Anxious 5(25) 1(5) 0
Awake-calm 13(65) 15(75) 5(25)a
Drowsy-RVC 2 (10) 4 (20) 10(50)b
Not RVC but to painful stimuli 0 0 5(25)
Not responding to painful stimuli 0 0 0
aP ≤ .005 versus group B
bP ≤ .005 versus group AInternational Journal of Pediatrics 5
Table 8: Recovery proﬁle.
After reversal of residual paralysis A B C
0.5mg/kg no. (%) 0.75mg/kgno. (%) 1.0mg/kgno. (%)
Time to spontaneous ventilation and extubation <5 18(90) 18(90) 16(80)
(minutes) 5–10 2(10) 2(10) 2(10)
15–60 0 0 2(10)
Time from premedication to full recovery Hours 3.20 ±0.41 3.17 ±0.38 3.39 ±0.38
in the 0.5mg/kg dose group received a GA induction score
of poor. In comparison, only 1 child in the 0.75mg/kg
dose group and none of the children in the 1.0mg/kg dose
group received a GA induction score of poor. GA induction
was reported as good or excellent for 85% of children
in the 1.0mg/kg dose group, as compared to 75% of the
children in the 0.75mg/kg dose group and 45% of the
children in the 0.5mg/kg dose group. These diﬀerences were
statisticallysigniﬁcantbetweenthe0.5mg/kgdosegroupand
the 1.0mg/kg dose group as well as between the 0.5mg/kg
dose group and the 0.75mg/kg dose group (P<. 05).
More of the children in the 0.5mg/kg dose group
(25%) were anxious on reversal of residual paralysis than
in the 0.75mg/kg dose group and the 1.0mg/kg dose
group (5%, 0%, resp.) (Table 7). The number of children
who were drowsy but arousable was the highest in the
1.0mg/kg dose group (50%) followed by the 0.75mg/kg
dose group (20%) and the 0.5mg/kg dose group (10%). The
diﬀerences observed between the 1.0mg/kg dose group and
the 0.5mg/kg dose group were statistically signiﬁcant. Also,
the percentage of children who were calm were signiﬁcantly
higher in the 0.75mg/kg dose group (75%) compared to the
0.5mg/kg dose group (25%).
3.5. Recovery Conditions. Most of the children in the three
groups recovered spontaneous ventilation and could be
e x t u b a t e dwi t h i n5m i n u t e s( Table 8). However, 2 children in
each of the 3 groups were extubated within 5–10 minutes of
reversal.Recoveryofspontaneousventilationandextubation
wasdelayedbyover15minutesin2childreninthe1.0mg/kg
dose group. Midazolam dose did not impact the overall
recovery times for children in any of the 3 groups, as the
averagetimeintervalfrompremedicationtofullrecoverywas
similar for all 3 groups.
4. Discussion
The population of children in this study has special charac-
teristics; they are extremely uncooperative, fearful, anxious,
and physically resistant. Uncooperative children, whether
due to repeated anesthesia, high anxiety, or psychological,
developmental, or mental disorders, should be appropriately
treated to avoid preoperative behavior problems [9]. In the
nineteenth century, it was shown that up to 25% of children
required physical restraint to facilitate anesthetic induction
[10].
Midazolam is the most commonly used drug for pre-
medication and is used in greater than 90% of surgical
cases involving premedication in the United States [11]. The
combination of the sedative and anxiolytic characteristics
is believed to create a calming eﬀect which makes children
less anxious when they are separated from their parents
and during mask placement [12]. Finley et al. [12] showed
that a midazolam-induced decrease in anxiety was more
pronounced for children with higher baseline levels of
anxiety.
Oral midazolam was found to be superior when com-
pared with other commonly used premedications. Oral
midazolamwasreportedtogiveamorepredictableandeﬀec-
tive sedation than oral diazepam [13]. It was also associated
with a faster and smoother recovery, when compared with
oral ketamine [14]. Patel and Meakin [15] also reported
greateranxiolysisafteroralmidazolam(0.5mg/kg)thanafter
a combination of diazepam (0.25mg/kg) with droperidol
(0.25mg/kg) or trimeprazine (2mg/kg).
Unfortunately, commercially prepared oral formulation
of midazolam is not available in many countries. A wide
variety of additives have been used, with the speciﬁc choice
beingamatteroflocalpracticeandpreference.Thisvariation
has resulted in formulas that diﬀer from practice to practice
intermsofchemicalcomposition,activedrugconcentration,
and pH [16]. Brosius and Bannister [16] reported that
IV midazolam yields more reliable sedation and corre-
spondingly higher plasma levels than an equivalent dose of
the commercially formulated and marketed preparation. In
another study, Cot´ e et al. [17]u s e d3d i ﬀerent doses of
commercial syrup in children (0.25, 0.5, and 1.0mg/kg, up
to a maximum of 20mg) and found that the smallest dose
(0.25mg/kg) was equally as eﬀective as the higher doses.
The problem with injectable midazolam is that it is very
bitter. In this study we used apple syrup as a carrier. We
found that it is easily available and convenient to use. Mishra
et al. [18] mixed IV midazolam with honey (5 times the
drug volume), which was well accepted by most of their
subjects. However, since this mixture is not transparent and
not a liquid, there is a question if its use violates the fasting
protocol for children [18].
Preoperative oral midazolam has proved eﬀective in
treating preoperative anxiety. Orally administered midazo-
lam can be given in a dose of 0.25 to 1.0mg/kg up to a total
dose of 20mg depending on the duration of surgery and the
anxiety level of the child. In this study, injectable midazolam
given orally as premedication was acceptable, eﬀective, and
safe in 0.75mg/kg dose, while the 0.50mg/kg dose was less
eﬀective. A dose of 1.0mg/kg may produce more sedation
over a 0.75mg/kg dose but does delay recovery and may
compromise safety.6 International Journal of Pediatrics
Feld et al. [19]alsoreportedasuperioranxiolysis30min-
utes after a 0.75mg/kg dose of oral midazolam as compared
to 0.25mg/kg and 0.5mg/kg doses or placebo. Similarly,
it was reported that the use of a 0.7mg/kg dose of oral
midazolam did not result in clinically respiratory depression
or upper airway obstruction, but in some children caused an
increased level of sedation beyond simple conscious sedation
[20]. In contrast, other studies found the dose of 0.5mg/kg
to be the most eﬀective. McMillan et al. reported no added
advantage but more side eﬀects for both 0.75mg/kg and
1.0mg/kg doses compared to the 0.5mg/kg dose [21]. We
found that the 0.75mg/kg dose gave superior eﬀects and
lesser side eﬀects than 0.5mg/kg dose. Also, we found that
increasing the dose to 1.0mg/kg did not give any added
advantage but exposed the children to more side eﬀects, a
ﬁnding corroborated by many studies [20, 21].
Theconﬂictingresultsofthestudiesaboutidealdoses for
midazolam as a premedicant are to be expected due to the
large range of heterogeneity in the studies in regard to drug
preparation, sedation scales used, patient characteristics, and
time between premedication and separation from parents.
As important as the dose of premedicant is, the age of
the child is also an important variable. Separation anxiety
usuallypeaksatapproximately1yearofage,buttoddlersand
preschoolers may also experience the distress of separations.
The extent of an individual child’s risk for stress reﬂects
genetics, personality, parenting, and previous life experience.
Children 1 to 5 years of age are at the highest risk for extreme
preoperative anxiety [22].
Clinical sedative eﬀects are seen within 5 to 10 minutes
of oral midazolam administration; the peak eﬀect is achieved
in 20 to 30 minutes [23]. Sedative eﬀects dissipate within
45 minutes in most cases. In many studies, midazolam has
been used orally at doses of 0.2–1.0mg/kg with onset of
action in 20 to 30 minutes [24]. In this study, the separation
time was ﬁxed at 30 minutes. We found a satisfactory
anxiolysis in 75% of the children after a 0.5mg/kg dose and
in 90% of the children after 1.0mg/kg dose of midazolam.
On arrival in the OR, the percentage of patients who had
desirable sedation (oriented, calm,or drowsy butresponding
to verbal command) were similar and marginally increased
to 80% in the 0.5 and 0.75mg/kg dose groups; however,
four children (20%) went into undesirable deep sedation in
the group that received higher dose of 1.0mg/kg. Similar
results were seen even when separation time was set to 45
minutes.
It is believed that anxiety may be reduced by increas-
ing the separation/premedication time. Timing should be
appropriatetoachieveonsettimeofpremedicant.However,a
study to determine the minimum time interval between oral
midazolam (0.5–1.0mg/kg) premedication and separation
from parents to ensure a smooth separation, researchers
found that children could be easily separated from their
parents after only 10 minutes [23].
Cox et al. [25] reviewed 30 papers regarding the use
of oral midazolam for premedication and concluded that
it is eﬀective in reducing both separation and induction
anxiety in children, with minimal eﬀect on recovery times.
We did not observe any signiﬁcant delay in recovery time
after 0.5 and 0.75mg/kg doses in children ranging from 2 to
6 years of age. Our ﬁnding of a premedication to recovery
period of 3 to 4 hours is in agreement with the report of
Reeves et al. [26], who reported that the mental function
returns to normal after 4 hours of giving oral midazolam as
a premedication.
Anterograde amnesia is a lack of recall of events
occurring from the time of administration of a drug
onwards. Midazolam aﬀects memory processes by impairing
the ability to acquire new information [27]. The amnesic
eﬀect of midazolam appears to be independent of the
sedation quality. Midazolam produces anterograde amne-
sia and may indirectly enhance the retention of material
learned before treatment as a consequence of the reduced
learning of information presented after the drug takes
eﬀect. The amnesic eﬀects of midazolam generally persist
f o r2 0t o3 0m i n u t e s[ 28]. Midazolam was found to
provide partial or complete amnesia in 90% of children
undergoing bone marrow aspiration [29]. In our study the
premedication time and the duration of surgery over last
to time convenient to test the amnesic eﬀect of midazo-
lam.
We concluded that a dose of 0.75mg/kg of injectable
midazolamgivenorallyaspremedicationforchildrenunder-
going complete dental rehabilitation is acceptable, eﬀective,
and safe. A dose of 0.50mg/kg is less eﬀective and a dose of
1.0mg/kg may produce undue over sedation.
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